The isothiocyanate sulforaphane is a promising molecule for development as a therapeutic agent for patients with metastatic
prostate cancer. Sulforaphane induces apoptosis in advanced prostate cancer cells, slows disease progression in vivo and is well
tolerated at pharmacological doses. However, the underlying mechanism(s) responsible for cancer suppression remain to be...
The isothiocyanate sulforaphane is a promising molecule for development as a therapeutic agent for patients with metastatic
prostate cancer. Sulforaphane induces apoptosis in advanced prostate cancer cells, slows disease progression in vivo and is well
tolerated at pharmacological doses. However, the underlying mechanism(s) responsible for cancer suppression remain to be...
The isothiocyanate sulforaphane is a promising molecule for development as a therapeutic agent for patients with metastatic
prostate cancer. Sulforaphane induces apoptosis in advanced prostate cancer cells, slows disease progression in vivo and is well
tolerated at pharmacological doses. However, the underlying mechanism(s) responsible for cancer suppression remain to be...
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms
linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family
members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone...